Genomic Profiling for <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer

Abstract

Despite guideline recommendations and significant therapeutic implications, overall biomarker testing rates in mCC remain suboptimal. Adherence to guideline-recommended biomarker testing would potentially reduce exposure to expensive and ineffective therapies, resulting in improved patient outcomes.